Clinical Trial Update: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing PEG-Intron to PEGASYS in chronic hepatitis B was terminated with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegylated interferon alfa-2a (PEGASYS) (pegylated interferon alfa-2a)
• Pegylated interferon alfa-2b (PEG-Intron) (pegylated interferon alfa-2b)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis B, Chronic | Phase 3 | Status: TERMINATED | Results posted: 2017-01-12